General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Product sales

Our complementary healthcare businesses address the changing needs of patients and societies worldwide. With innovative pharmaceuticals at the core, we are also a global leader in generics, vaccines and consumer health products.

Read more about the 2013 sales of our top 20 pharmaceutical products in the table below.

Product Full Year 2013 Product Sales Business franchise
USD m % change (USD)
Glivec 4,693 0% Oncology
Diovan 3,524 -20% Primary care
Lucentis 2,383 -1% Ophthalmics
Gilenya 1,934 62% Neuroscience
Sandostatin 1,589 5% Oncology
Exforge 1,456 8% Primary care
Afinitor / Votubia 1,309 64% Oncology
Tasigna 1,266 27% Oncology
Galvus 1,200 32% Primary care
Exelon / Exelon Patch 1,032 -2% Neuroscience
Exjade 893 3% Oncology
Sandimmum / Neoral 750 -9% Integrated Hospital Care
Voltaren 675 (excl. OTC) -11% Established medicines
Myfortic 637 10% Integrated Hospital Care
Xolair 613 22% Primary Care
Zometa 600 -53% Oncology
Ritalin 594 7% Established medicines
Comtan / Stalevo 401 -24% Neuroscience
TOBI 387 22% Critical Care
Femara 384 -12% Oncology

Stock chart
Q3 Results 2013

On Thursday, April 24, Novartis will announce its results for the first quarter of 2014